Loading...
•
Dec 31, 2020
Denali Therapeutics Q4 2020 Earnings Report
Reported net income and increased collaboration revenue driven by the Biogen Collaboration Agreement.
Key Takeaways
Denali Therapeutics reported a net income of $244.9 million for Q4 2020, a significant increase compared to the net loss of $54.0 million in Q4 2019. The increase was primarily driven by $307.4 million of revenue recognized under the Biogen Collaboration Agreement. The company's cash, cash equivalents, and marketable securities were $1.5 billion as of December 31, 2020.
Reported positive 3-month data from Phase 1/2 study of DNL310 in patients with Hunter syndrome (MPS II).
Added five new Enzyme Transport Vehicle (ETV) programs for LSDs.
Completed Phase 1b study of DNL151 (BIIB122), supporting late-stage development.
Announced RIPK1 program updates, including Sanofi's submission of an investigational new drug (IND) application for DNL788 (SAR443820).
Forward Guidance
Denali anticipates an increase of approximately 20-25% in cash operating expenses compared to 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...